Dapagliflozin: clinical considerations in T2D {#FPar1}
=============================================

Lowers glucose levels independently of insulin actionProvides effective glycaemic control and reduces bodyweight and BPReduces rate of CV death or HHF, does not adversely affect MACE and possibly reduces progression of renal diseaseLow risk of hypoglycaemia, while genital infections and DKA are more common than with placebo

Introduction {#Sec1}
============

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a relatively new class of antihyperglycaemic agents (AHAs) for the treatment of type 2 diabetes (T2D) \[[@CR1]--[@CR3]\]. These agents reduce reabsorption of glucose in the kidneys and facilitate its excretion in the urine by inhibiting the high-capacity glucose transporter SGLT2 located in the proximal convoluted tubule, thereby lowering glucose levels independently of insulin action \[[@CR1], [@CR2]\]. This unique mechanism of action of SGLT2 inhibitors complements that of other classes of AHAs, allowing for their use as combination therapy with other AHAs, including insulin. Dapagliflozin (Forxiga^®^) is one such SGLT2 inhibitor that is approved for the treatment of T2D in various countries worldwide, including the EU and USA. The pharmacological properties and clinical use of dapagliflozin in adults with T2D have been extensively reviewed previously in *Drugs* \[[@CR4], [@CR5]\]. This article, written from an EU perspective, focuses on recent trials, including the large DECLARE-TIMI 58 cardiovascular (CV) outcomes trial in patients with T2D with or without established cardiovascular disease (CVD). Dapagliflozin is also available as fixed-dose dapagliflozin/metformin (Xigduo^®^) and dapagliflozin/saxagliptin (Qtern^®^) tablets.

Pharmacological Properties {#Sec2}
==========================

Dapagliflozin is a highly potent (inhibitory constant 0.55 nmol/L) and reversible SGLT2 inhibitor that is \> 1400 times more selective for SGLT2 than SGLT1, the main transporter responsible for glucose absorption in the gut \[[@CR6], [@CR7]\]. Dapagliflozin increased the amount of glucose excreted in the urine and improved both fasting (FPG) and post-prandial plasma glucose levels in patients with T2D \[[@CR8]\]. Urinary glucose excretion (glucuresis) was seen after the first dose of dapagliflozin, was continuous during the 24 h dosing interval and maintained over the course of therapy \[[@CR7], [@CR8]\]. Dapagliflozin-induced glucuresis in patients with T2D was associated with caloric loss and a modest reduction in bodyweight, as well as mild osmotic diuresis and transient natriuresis \[[@CR7], [@CR9], [@CR10]\]. The loss in bodyweight with SGLT2 inhibitors is less than that calculated from calorie loss due to glucuresis, which may be because of compensatory mechanisms such as increased energy intake \[[@CR11]\]. A modest decrease in blood pressure (BP) was also seen with dapagliflozin, which may be explained by a decrease in circulating volume because of the diuretic/natriuretic properties of the drug \[[@CR10]\]. The effects of dapagliflozin on glycaemic parameters, bodyweight and BP in large clinical trials in patients with T2D are summarized in Sect. [3](#Sec3){ref-type="sec"}.

Dapagliflozin is rapidly absorbed after oral administration, with peak plasma concentrations usually reached within 2 h (fasted state) \[[@CR7]\]. After a 10 mg dose, the absolute oral bioavailability of dapagliflozin is 78%. The mean steady-state volume of distribution of dapagliflozin is 118 L and it is ≈ 91% protein bound. Dapagliflozin pharmacokinetics are not affected by food to a clinically meaningful extent. Dapagliflozin is largely metabolized by UGT1A9 (an enzyme in the liver and kidneys) to its major inactive metabolite 3-O-glucuronide; the major and other metabolites of dapagliflozin do not contribute to its glucose-lowering effects. Dapagliflozin and its metabolites are largely excreted in the urine, with 75% of a dose recovered in the urine (\< 2% as unchanged parent drug) and 21% in the faeces (≈ 15% as unchanged parent drug). After single-dose dapagliflozin 10 mg in healthy subjects, the mean plasma terminal elimination half-life of dapagliflozin was 12.9 h \[[@CR7]\].

Therapeutic Efficacy of Dapagliflozin {#Sec3}
=====================================

Glycaemic and Other Outcomes {#Sec4}
----------------------------

As reviewed previously in *Drugs* \[[@CR4], [@CR5]\], numerous randomized, double-blind, multicentre, phase 3 trials with dapagliflozin as monotherapy and combination therapy have demonstrated its efficacy in improving glycaemic control and reducing bodyweight and BP in a broad spectrum of patients with T2D, including those with high baseline HbA~1c~ (≥ 9%) \[[@CR12]\] and the elderly (aged ≥ 65 years) \[[@CR13]\]. Results from more recent trials, including special populations such as patients with chronic kidney disease (CKD) stage 3A \[[@CR14]\], hypertension \[[@CR15], [@CR16]\] or CVD \[[@CR17], [@CR18]\], are summarized in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}).Table 1Efficay of oral dapagliflozin 10 mg once daily as add-on therapy in randomized, double-blind, multicentre, phase 3--4 trials and extensions in patients with T2DStudy (mean diabetes duration)Duration (weeks)Treatment (no. of pts)Adjusted mean^a^ change from BL \[BL\]HbA~1c~ \< 7% (% of pts)HbA~1c~^b^ (%)FPG (mmol/L)BW (kg)SBP^c^ (mmHg)Matthaei et al. \[[@CR57], [@CR62]\] (≈ 9 years)24DAPA + MET + SU (108)− 0.86\*\*\* \[8.1\]− 1.9\*\*\* \[9.3\]− 2.7\*\*\* \[89\]− 4.0\*^c^ \[135\]32\*\*\*PL + MET + SU (108)− 0.17 \[8.2\]− 0.04 \[10.2\]− 0.6 \[90\]− 0.3^c^ \[136\]1152 \[[@CR57]\]DAPA + MET + SU− 0.8− 1.5− 2.9− 1.027PL + MET + SU− 0.2+ 0.6− 1.0+ 1.111Matheiu et al. \[[@CR63]\] (≈ 8 years)24DAPA + SAX + MET (160)− 0.82\*\*\* \[8.2\]− 1.8\*\*\* \[9.9\]− 1.9\*\*\* \[86\]− 1.9\* \[NA\]38\*\*\*PL + SAX + MET (160)− 0.10 \[8.2\]− 0.3 \[9.8\]− 0.4 \[88\]+ 2.0 \[NA\]1252 \[[@CR58]\]DAPA + SAX + MET− 0.74− 1.5− 2.1NA29PL + SAX + MET+ 0.07+ 0.6− 0.4NA13Müller-Wieland et al. \[[@CR64]\] (≈ 7 years)52DAPA + SAX + MET (312)− 1.2^††d^ \[8.3\]− 2.1^††^ \[10.4\]− 3.2^††^ \[95\]− 6.4^††^ \[139\]40DAPA + MET (311)− 0.82^d^ \[8.3\]− 1.6 \[10.6\]− 3.5^††^ \[98\]− 5.6^††^ \[138\]20^††^GLIM + MET (309)− 0.99^d^ \[8.3\]− 1.5 \[10.4\]+ 1.8 \[98\]− 1.6 \[139\]34Handelsman et al. \[[@CR65]\] (≈ 8 years)26DAPA + SAX + MET (232)− 1.41^††^ \[8.8\]− 1.8^†††^ \[9.5\]− 1.9^†††^NA37^†^SIT + MET (229)− 1.07 \[8.9\]− 0.6 \[9.7\]− 0.5NA2552DAPA + SAX + MET− 1.29− 1.4− 2.3− 2.6 \[130\]33SIT + MET− 0.81− 0.2− 0.8+ 2.5 \[129\]20Frias et al. \[[@CR61]\] (DURATION-8) (≈ 7 years)28DAPA + EXN + MET (228)− 2.0^§†^ \[9.3\]− 3.66^§††^ \[10.8\]− 3.6^§††^ \[92\]− 4.3^†^ \[131\]45^§††^DAPA + PL + MET (227)− 1.4 \[9.3\]− 2.73 \[10.5\]− 2.2 \[91\]− 1.8^†^ \[130\]19PL + EXN + MET (230)− 1.6 \[9.3\]− 2.54 \[10.5\]− 1.6 \[89\]− 1.2 \[129\]27104 \[[@CR60]\]^e^DAPA + EXN + MET− 1.70^§†^− 2.70^§††^− 2.5^†^− 3.1^†^NADAPA + PL + MET− 1.06− 1.20− 3.0− 1.1NAPL + EXN + MET− 1.29− 1.70− 0.8− 0.1NAVilsbøll et al. \[[@CR66]\]^e^ (NA)24DAPA + SAX + MET ± SU (324)− 1.7^d^ \[9.0\]− 1.5^††^NA21^†f^INS + MET ± SU (319)− 1.5^d^ \[9.0\]+ 2.1NA13^f^52 \[[@CR59]\]^e^DAPA + SAX + MET ± SU− 1.51^†^− 1.83^††^NA15^††f^INS + ME ± SU− 1.26+ 2.75NA7^f^No statistical comparisons available for two extension studies \[[@CR57], [@CR58]\] and nominal*p* values reported for two others \[[@CR59], [@CR60]\]*BL* baseline, *BW* bodyweight, *DAPA* oral dapagliflozin 10 mg/day, *EXN* subcutaneous exenatide-extended release 2 mg once weekly, *FPG* fasting plasma glucose, *GLIM* oral glimepiride 4 mg/day, *INS* titrated insulin glargine (FPG goal ≤ 5.5 mmol/L), *HbA*~*1c*~ glycated haemoglobin, *MET* oral metformin ≥ 1500 mg/day, *NA* not available, *PL* placebo, *pts* patients, *SIT* oral sitagliptin 100 mg/day, *SAX* oral saxagliptin 5 mg/day, *SBP* systolic blood pressure, *SU* oral sulfonylurea ≥ 50% of maximum dose\**p* \< 0.05, \*\**p* ≤ 0.001, \*\*\**p* \< 0.0001 vs. PL; ^†^*p* \< 0.05, ^††^*p* ≤ 0.001, ^†††^*p* \< 0.0001 vs. active comparator; ^§^*p* \< 0.001 vs. DAPA^a^Values are least-squares mean in two studies \[[@CR60], [@CR61]\]^b^Primary endpoint for the main study^c^SBP assessed at week 8 in one study \[[@CR62]\]^d^Noninferiority between treatment groups was demonstrated^e^Abstract presentation^f^Proportion of patients achieving target HbA1c \< 7% without hypoglycaemiaTable 2Efficay of oral dapagliflozin 10 mg once daily as add-on to existing antidiabetic therapy in randomized, double-blind, multicentre, phase 3 trials and extensions in patients with T2D and high-risk of cardiovascular complicationsStudyDuration (weeks)Treatment (no. of pts)Adjusted mean change from BL \[BL\]3-item response^a^ (% of pts)HbA~1c~ (%)FPG (mmol/L)Bodyweight (kg)SBP (mmHg)In pts with hypertension on ACEi or ARB therapy Weber et al. \[[@CR15]\]12DAPA (302)− 0.6\*\*\*^b,c^ \[8.1\]− 0.7^c^ \[8.8\]− 1.0^c^ \[86\]− 10.4\*\*^b,c^ \[150\]PL (311)− 0.1^b,c^ \[8.0\]+ 0.4^c^ \[8.9\]− 0.3^c^ \[84\]− 7.3^b,c^ \[150\]In pts with hypertension on combination antihypertensive therapy Weber et al. \[[@CR16]\]12DAPA (225)− 0.63\*\*\*^b,c^ \[8.1\]− 1.0^c^ \[9.0\]− 1.44^c^ \[88\]− 11.9\*\*^b,c^ \[151\]PL (224)− 0.02^b,c^ \[8.0\]+ 0.2^c^ \[8.9\]− 0.59^c^ \[90\]− 7.6^b,c^ \[151\]In pts with CVD Leiter et al. \[[@CR17]\]24DAPA (480)− 0.3\*\*^b^ \[8.0\]− 0.8\*\* \[9.0\]− 2.5\*\* \[95\]− 1.9\*\* \[135\]10\*\*^b^PL (482)+ 0.1^b^ \[8.1\]+ 0.6 \[9.2\]− 0.6 \[93\]+ 0.9 \[135\]1.9^b^52DAPA− 0.5− 0.9− 3.2− 3.610.6PL0.0+ 0.2− 1.1− 0.93.1 Cefalu et al. \[[@CR18]\]24DAPA (455)− 0.38\*\*\*^b^ \[8.2\]− 0.57\* \[8.9\]− 2.6\*\*\* \[93\]− 2.99\* \[133\]12\*\*\*^b^PL (459)+ 0.08^b^ \[8.1\]+ 0.35 \[8.8\]− 0.3 \[94\]− 1.0 \[133\]1^b^52DAPA− 0.44− 0.96− 2.9− 3.407PL+ 0.22− 0.01− 0.3+ 0.180.7No statistical comparisons are available for extension studies*ACEi* angiotensin-converting enzyme inhibitor, *ARB* angiotensin receptor blocker*, BL* baseline, *CVD* cardiovascular disease, *DAPA* dapagliflozin, *FPG* fasting plasma glucose, *HbA*~*1c*~ glycated haemoglobin, *PL* placebo, *pts* patients, *SBP* systolic blood pressure\**p* \< 0.05, \*\**p* ≤ 0.001, \*\*\**p* \< 0.0001 vs. PL^a^Defined as the proportion of pts achieving combined reduction in HbA1c of ≥ 5.5%, bodyweight of ≥ 3% and SBP of ≥ 3 mmHg^b^Coprimary endpoint^c^Hierarchical testing was used for the coprimary (mean change in seated SBP followed by mean change in HbA1c) and secondary endpoints

In a randomized, double-blind, multinational, phase 3 study in patients inadequately controlled with metformin (*n* = 182), add-on dapagliflozin reduced bodyweight largely by reducing fat mass relative to placebo, with fat mass accounting for approximately two-thirds of the total weight loss \[[@CR19]\]. At week 24, patients receiving add-on dapagliflozin 10 mg once daily had significantly lower total bodyweight (primary endpoint; difference from placebo − 2.1 kg; baseline ≈ 92 kg; *p* \< 0.0001), smaller waist circumference (− 1.5 cm; baseline ≈ 105 cm *p* = 0.0143) and less fat mass as assessed by dual X-ray absorptiometry (DXA) (− 1.5 kg; baseline ≈ 33 kg; *p* = 0.0001) than those receiving add-on placebo. A rapid decline in bodyweight was seen in the first few weeks of dapagliflozin treatment, with a gradual decline thereafter that had not plateaued at week 24. This change in bodyweight was reflected in the daily spot urinary glucose level, which showed an initial rapid increase and stable levels thereafter, supporting the DXA findings that the loss in bodyweight and fat mass with dapagliflozin was largely because of caloric loss from glucosuria. However, the initial rapid decline in bodyweight in dapagliflozin recipients may partly be because of fluid loss \[[@CR19]\].

Additionally, the proportion of patients with a decrease in bodyweight of ≥ 5% was significantly higher in patients receiving dapagliflozin than those receiving placebo (31 vs. 4%; p \< 0.0001) \[[@CR19]\]. Moreover, magnetic resonance imaging in a substudy in 80 patients showed that both visceral and subcutaneous adipose tissues were reduced in dapagliflozin relative to placebo recipients (difference from placebo − 258 and − 185 cm^3^, respectively; both nominal *p* \< 0.05) \[[@CR19]\]. The reductions in bodyweight, fat mass and waist circumference with add-on dapagliflozin versus add-on placebo at week 24 were maintained over 102 weeks' therapy \[[@CR20]\].

### Patients with Hypertension {#Sec5}

Dapagliflozin 10 mg once daily reduced SBP and improved glycaemic control in two phase 3 studies in patients with inadequately controlled T2D and hypertension despite receiving antihypertensive therapy (angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) therapy alone \[[@CR15]\] or in combination with one other antihypertensive \[[@CR16]\]). At week 12, mean SBP and HbA~1c~ were significantly lower with dapagliflozin than placebo in both studies (first and second coprimary endpoints, respectively) (Table [2](#Tab2){ref-type="table"}). A post hoc analysis of one study suggested that SBP was lowered with dapagliflozin to a greater degree in patients receiving a β blocker or a calcium-channel blocker as their additional antihypertensive drug than in those receiving a thiazide diuretic \[[@CR16]\].

### Patients with Cardiovascular Disease {#Sec6}

Dapagliflozin 10 mg once daily improved glycaemic control and reduced bodyweight and SBP when added to usual background therapy in two phase 3 studies in patients with inadequately controlled T2D (HbA~1c~ 7--10.5% across the studies) and pre-existing CVD and hypertension \[[@CR17], [@CR18]\]. At week 24, in both studies, HbA~1c~ was lowered to a significantly greater extent with add-on dapagliflozin than add-on placebo, and a significantly greater proportion of patients in the dapagliflozin group had a 3-item response than in the placebo group (coprimary endpoints; Table [2](#Tab2){ref-type="table"}) \[[@CR17], [@CR18]\]. Treatment benefits with dapagliflozin were maintained at week 52 in the extension studies \[[@CR17], [@CR18]\]. A significantly (*p* \< 0.005) greater proportion of patients in the dapagliflozin than placebo groups in both studies achieved a target HbA~1c~ of \< 7% at week 24 (19 vs. 13% \[[@CR17]\]; 16 vs. 8% \[[@CR18]\]), with the between-group differences maintained at week 52 (19 vs. 10% \[[@CR17]\]; 15 vs. 5% \[[@CR18]\]). Efficacy of dapagliflozin was maintained during longer-term treatment in a second extension of 52 weeks (total 104 weeks' therapy, according to a post hoc pooled analysis of the two studies \[[@CR21]\].

In a pooled analysis of five, phase 2--3 clinical trials of ≤ 52 weeks' duration, patients with T2D and a history of HF had clinically meaningful reductions from baseline in HbA~1c~ (placebo-adjusted mean change − 0.55%; baseline 8.2%), bodyweight (− 2.7 kg; baseline ≈ 97 kg) and SBP (− 2.1 mmHg; baseline ≈ 134 mmHg) with dapagliflozin 10 mg monotherapy or add-on therapy to other AHA regimens (*n* = 171) relative to placebo/active comparator (*n* = 149) \[[@CR22]\].

### Patients with Renal Impairment {#Sec7}

A post hoc analysis of a phase 2/3 study suggested treatment benefit with dapagliflozin in patients with CKD stage 3A (eGFR ≥ 45 and \< 60 mL/min 1.73 m^2^) \[[@CR14]\], with findings supported by the randomized, double-blind, multinational, phase 3 DERIVE study \[[@CR23]\]. In DERIVE, patients with inadequately controlled T2D (HbA~1c~ 7--11%), a BMI of 18--45 kg/m^2^ who were receiving other AHA regimens and who had CKD stage 3A were randomized to receive 24 weeks of dapagliflozin 10 mg once daily (*n* = 159) or placebo (*n* = 161). At week 24, dapagliflozin significantly (*p* = 0.05) lowered HbA~1c~ (primary endpoint; placebo-adjusted mean change − 0.34; baseline ≈ 8.2%), FPG (− 0.9 mmol/L; baseline ≈ 10 mmol/L), bodyweight (− 1.3 kg; baseline ≈ 90 kg) and SBP (− 3.1 mmHg; baseline ≈ 135 mmHg) relative to placebo \[[@CR23]\]. A randomized, double-blind, multinational, phase 3 study (CompoSIT-R) in patients inadequately controlled with metformin ± sulfonylurea (HbA~1c~ 7--9.5%) and who had mild renal impairment (eGFR ≥ 60 to \< 90 mL/min/1.73 m^2^) showed that the addition of sitagliptin 100 mg once daily (*n* = 307) was noninferior (primary hypothesis) and superior to that of dapagliflozin 10 once daily (*n* = 306) in improving glycaemic control \[HbA~1c~ least squares (LS) mean change from baseline − 0.51 vs. − 0.36%; baseline ≈ 7.8% *p* = 0.006\] \[[@CR24]\].

Cardiovascular and Renal Outcomes {#Sec8}
---------------------------------

The effects of dapagliflozin on CV and renal outcomes were assessed in the randomized, double-blind phase 3 DECLARE-TIMI 58 trial in patients aged ≥ 40 years with T2D (HbA~1c~ ≥ 6.5 to \< 12%) and established atherosclerotic CVD (ASCVD) or multiple risk factors for ASCVD \[[@CR25]\]. Patients were also required to have creatinine clearance (CL~CR~) ≥ 60 mL/min. Patients with multiple risk factors were men aged ≥ 55 years or women aged ≥ 60 years with one or more of traditional risk factors, such as hypertension, dyslipidaemia \[i.e. low-density lipoprotein level \> 130 mg/dL (3.36 mmol/L) or use of lipid-lowering therapies\] or use of tobacco \[[@CR25]\].

The study was originally designed to assess the effect of dapagliflozin on the primary safety outcome of major adverse CV events (MACE) \[[@CR25], [@CR26]\]. However, based on the findings of the EMPA-REG OUTCOME trial of empagliflozin \[[@CR27]\] that emerged during the conduct of DECLARE-TIMI 58, its study design was modified to include dual primary efficacy outcomes of MACE and the composite of CV death and hospitalization for heart failure (CV death/HHF) \[[@CR25], [@CR26]\]. The two prespecified secondary endpoints were renal composite outcome (see Table [3](#Tab3){ref-type="table"} for definition) and death from any cause \[[@CR25], [@CR26]\]. At baseline, patients (*n* = 17,160 randomized) had a mean age of 64 years and 41% had established ASCVD, including coronary artery disease (33% of patients) and heart failure (HF; 10%) \[[@CR25]\]. The mean duration of diabetes was ≈ 11 years, mean HbA~1c~ was 8.3% and the mean estimated glomerular filtration rate (eGFR) was 85 mL/min/1.73 m^2^ (45 and 7% of patients had an eGFR of 60--90 and \< 60 mL/min/1.73 m^2^, respectively\]. Patients were randomized to receive dapagliflozin 10 mg once daily or placebo in addition to other AHAs; use of other AHAs was at the discretion of the treating physician. The median follow-up duration was 4.2 years (69,547 patient-years) \[[@CR25]\].Table 3Efficacy of oral dapagliflozin 10 mg once daily in in the DECLARE-TIMI 58 cardiovascular outcomes trial \[[@CR25]\]OutcomesEvent rate (%) \[per 1000 patient-years\]DAPA (*n* = 8582)PL (*n* = 8578)HR vs. PL (95% CI)**Primary efficacy outcomes**CV death or HHF^a^4.9 \[12.2\]5.8 \[14.7\]0.83 (0.73--0.95)\*^b^MACE^a^8.8 \[22.6\]9.4 \[24.2\]0.93 (0.84--1.03)^b^**Secondary outcomes**^**c**^Renal composite^a,d^4.3 \[10.8\]5.6 \[14.1\]0.76 (0.67--0.87)Death from any cause^a^6.2 \[15.1\]6.6 \[16.4\]0.93 (0.82--1.04)**Other outcomes**^**c**^Additional renal composite^a,e^1.5 \[3.7\]2.8 \[7.0\]0.53 (0.43--0.66)HHF2.5 \[6.2\]3.3 \[8.5\]0.73 (0.61--0.88)MI4.6 \[11.7\]5.1 \[13.2\]0.89 (0.77--1.01)Ischaemic stroke2.7 \[6.9\]2.7 \[6.8\]1.01 (0.84--1.21)Death from CV cause2.9 \[7.0\]2.9 \[7.1\]0.98 (0.82--1.17)Death from non CV cause2.5 \[6.0\]2.8 \[6.8\]0.88 (0.73--1.06)*CV* cardiovascular, DAPA dapagliflozin, *eGFR* estimated glomerular filtration rate, *HHF* hospitalization for heart failure, *HR* hazard ratio, *MACE* major adverse cardiovascular event (CV death, MI or ischemic stroke), *MI* myocardial infarction, *PL* placebo\**p* = 0.005^a^Prespecified outcomes^b^After demonstrating the noninferiority of DAPA vs. PL (p \< 0.001) for the primary safety outcome of MACE, superiority (two-sided α level of 0.023) of DAPA over PL was demonstrated for the endpoint of CV death or HHF, but not for MACE^c^Statistical analyses are hypothesis generating because of hierarchical testing^d^Defined as ≥ 40% decrease in eGFR to \< 60 ml/min/1.73 m^2^, end-stage renal disease, or death from renal or CV cause^e^Defined as ≥ 40% decrease in eGFR to \< 60 ml/min/1.73 m^2^, end-stage renal disease, or death from renal cause

Dapagliflozin significantly lowered the rate of CV death/HHF versus placebo, but there was no significant between-group difference in the rate of MACE (dual efficacy endpoints assessed after confirming the noninferiority of dapagliflozin and placebo for the primary safety outcome of MACE) (Table [3](#Tab3){ref-type="table"}) \[[@CR25]\]. As MACE was not lowered to a significant extent with dapagliflozin versus placebo, analyses of secondary and other endpoints (Table [3](#Tab3){ref-type="table"}) conducted hierarchically were only hypothesis generating. The lower rate of the composite endpoint of CV death/HHF in dapagliflozin recipients was attributed to the lower rate of hospitalization for heart failure (HHF) with dapagliflozin than placebo; the rate of CV death was generally similar between the two groups (Table [3](#Tab3){ref-type="table"}). Sensitivity analyses of the primary efficacy endpoints supported the findings of the primary analysis of the outcomes \[[@CR25]\].

In terms of secondary and other endpoints, results suggest that dapagliflozin reduces the likelihood of progression of renal disease, as indicated by lower incidences of the renal composite and additional renal composite outcomes in dapagliflozin than placebo recipients (Table [3](#Tab3){ref-type="table"}) \[[@CR25]\]. For the individual components of the renal outcomes, dapagliflozin relative to placebo was associated with significant reduction in sustained decline in eGFR by ≥ 40% to \< 60 mL/min per 1.73 m^2^ \[hazard ratio (HR) 0.54; 95% CI 0.43--0.67; *p*\< 0·0001), end-stage renal disease (ESRD; HR 0.31; 95% CI 0.13--0.79; *p* = 0.013), and renal death or ESRD (HR 0.41; 95% CI 0.20--0.82; *p* = 0.012) \[[@CR28]\]. The mean decrease from baseline in eGFR was significantly (*p* \< 0.0001) greater with dapagliflozin than placebo at 6 months, but had equalized with placebo by 2 years, and was significantly (*p* \< 0.0001) less than that with placebo by 3 and 4 years after randomization \[[@CR28]\].

The rates of death from any cause, myocardial infarction (MI), ischaemic stroke and death from non-CV causes were generally similar between the two groups (Table [3](#Tab3){ref-type="table"}). CV risk factors were improved with dapagliflozin, including the level of HbA~1c~, which was lower in dapagliflozin than placebo recipients throughout the trial (average LS mean absolute difference between groups 0.42%; 95% CI 0.40--0.45) \[[@CR25]\]. Bodyweight (LS mean difference between groups 1.8 kg; 95% CI 1.7--2.0), SBP (2.7 mmHg; 95% CI 2.4--3.0) and diastolic BP (DBP; 0.7 mmHg; 95% CI 0.6--0.9) were also lower with dapagliflozin than placebo during the trial \[[@CR25]\].

### Subgroup Analyses {#Sec9}

In subgroups analyses, the benefit of dapagliflozin in preventing CV death/HHF was consistent across subgroups, regardless of the history of CVD \[patients with ASCVD (HR 0.83; 95% CI 0.71--0.98) or multiple risk factors (HR 0.84; 95% CI 0.67--1.04)\], history of HF (yes or no) or baseline eGFR (≥ 90, 60 to \< 90, or \< 60 mL/min/1.73 m^2^) (all *p* interactions nonsignificant) \[[@CR25]\]. The rate of MACE did not differ significantly between dapagliflozin and placebo recipients in any subgroup (all *p* interactions nonsignificant), including patients with ASCVD (HR 0.90; 95% CI 0.79--1.02) or multiple risk factors (HR 1.01; 95% CI 0.86--1.20). Treatment benefit with dapagliflozin relative to placebo in terms of lower rate of progression of renal disease was seen regardless of the history of CVD, HF or CKD at baseline (all *p* interactions nonsignificant) \[[@CR25]\].

A prespecified subgroup analysis suggested robust clinical benefit with dapagliflozin in the high-risk subgroup of patients with T2D and prior MI (median duration from last event 5.4 years) both in terms of MACE and the composite of CV death/HHF \[[@CR29]\]. Dapagliflozin significantly reduced MACE by 16% (HR 0.84; 95% CI 0.72--0.99; *p* = 0.04) in patients with prior MI (*n* = 3584), but not in those with no prior MI (*n* = 6771; HR 1.00; 95% CI 0.88--1.13) or no prior MI but with established ASCVD (*n* = 3390; HR 0.98; 95% CI 0.81--1.19). The lower rate of MACE in patients with prior MI was largely because of a lower rate of recurrent MI (HR 0.78; 95% CI 0.63--0.95). The absolute risk reduction (ARR) for MACE in patients with prior MI was 2.6% and the number needed to treat (NNT) over 4 years was 39. The treatment benefit with dapagliflozin in terms of MACE appeared to be greater the closer the patients were to the last acute event (*p* interaction trend 0.007), with the greatest benefit in patients with a recent MI (\> 12 to 24 months). In contrast to MACE, a treatment benefit (HR \< 1) for CV death/HHF was seen with dapaglilozin relative to placebo in all subgroups, i.e. patients with prior MI (HR 0.81; 95% CI 0.65--1.00, *p* = 0.046), those with no prior MI (HR 0.85; 95% CI 0.72--1.00) and patients with no prior MI but with ASCVD (HR 0.87; 95% CI 0.68--1.12); the ARR in the three patient groups was 1.9% (NNT over 4 years was 53), 1.0% and 0.5% respectively \[[@CR29]\].

Another prespecified subgroup analysis assessed the efficacy of dapagliflozin in patients with T2D and HF with reduced ejection fraction \[HFrEF; ejection fraction (EF) \< 45%; *n* = 671\] and in those without HFrEF \[comprising patients with HF without known reduced EF (*n* = 1316) and patients without HF (*n* = 15,173)\] \[[@CR30]\]. Dapagliflozin reduced CV death/HHF to a greater extent in patients with HFrEF (HR vs. placebo 0.62; 95% CI 0.45--0.86) than in those without HFrEF (HR vs. placebo 0.88, 95% CI 0.76--1.02) (*p* interaction 0.046), with the difference largely because of a reduction in CV death in patients with HFrEF (HR vs. placebo 0.55; 95% CI 0.34--0.90, *p* = 0.02) compared with patients without known HFrEF (HR vs. placebo 1.08; 95% CI 0.89--1.31). All-cause death was also significantly reduced with dapagliflozin relative to placebo in patients with HFrEF (HR 0.59; 95% CI 0.40--0.88, *p* = 0.01), but not in those without known HFrEF (HR 0.97; 95% CI 0.86--1.10) (*p* interaction 0.016). The NNT over 4 years for CV death/HHF, CV death and all-cause death in patients with HFrEF was 11, 19 and 16, respectively. In contrast, HHF was reduced with dapagliflozin regardless of baseline EF, with similar reductions in patients with HFrEF (HR 0.64; 95% CI 0.43--0.95) and without known HFrEF (HR 0.76; 95% CI 0.62--0.92) (*p* interaction 0.45) \[[@CR30]\].

Real-World Studies {#Sec10}
------------------

Several large real-world studies (*n* ≥ 1900) supported the efficacy of dapagliflozin in patients with T2D \[[@CR31]--[@CR36]\]. Dapagliflozin (in addition to other AHAs) for 12 weeks to \> 12 − 24 months numerically or significantly improved efficacy outcomes, including HbA~1c~, bodyweight and SBP in database studies in the UK \[[@CR31]\] and USA \[[@CR32]\], a Korean postmarketing study \[[@CR33]\] and a prospective, multicentre, observational study in India \[[@CR34]\]. During 3--6 months' follow-up in a study based on clinical data from a Canadian registry for patients with T2D (for \> 6 months) who received dapagliflozin (*n* = 1850), a dipeptidyl peptidase-4 inhibitor (DPP-4i; *n* = 1341) or a sulfonylurea (*n* = 579), significantly more patients receiving dapagliflozin than those receiving a DPP-4i or a sulfonylurea had HbA~1c~ reduction of ≥ 0.5%, any weight loss and SBP reduction of ≥ 5.0 mmHg (composite primary endpoint; 26 vs. 21 and 15%; *p* \< 0.05) \[[@CR35]\]. Another study, the DARWIN-T2D Italian, multicentre, retrospective study, found that treatment with dapagliflozin (*n* = 830) or a glucagon-like peptide-1 receptor agonist (GLP-1RA; *n* = 811) significantly (*p* \< 0.05) reduced HbA~1c~, bodyweight and SBP \[[@CR36]\]. In comparison, treatment with a DPP-4i (*n* = 2999) significantly (*p* \< 0.05) reduced two of the three parameters, i.e. HbA~1c~ and bodyweight, and gliclazide (a sulfonylurea; *n* = 2111) significantly (*p* \< 0.05) lowered only HbA~1c~. While the reduction from baseline in HbA~1c~ was generally similar in all four treatment groups (change from baseline − 0.7, − 0.6, − 0.6 and − 0.6%), treatment with dapagliflozin or a GLP-1RA was associated with numerically greater improvements in bodyweight (change from baseline − 2.7 and − 2.4 vs. − 0.5 and − 0.1 kg) and SBP (− 3.0 and − 1.4 vs. − 0.7 and + 0.1 mmHg) than treatment with a DPP-4i or gliclazide \[[@CR36]\].

The efficacy of dapagliflozin in preventing CV events in DECLARE-TIMI 58 was supported by real-world experience in the CVD-REAL Nordic study, based on data from nationwide registries in Denmark, Norway and Sweden for patients with T2D who were prescribed AHAs during 2012--2015 \[[@CR37]\]. Dapagliflozin (*n* = 10,227 patients) significantly lowered the risk of MACE (non-fatal MI, non-fatal stroke or CV mortality; HR 0.79; 95% CI 0.67--0.94), HHF (HR 0.62; 95% CI 0.50--0.77) and all-cause death (HR 0.59; 95% CI 0.49--0.72) versus DPP-4is (*n* = 30,681) after a mean follow-up of 0.95 years \[[@CR37]\].

Tolerability of Dapagliflozin {#Sec11}
=============================

Dapagliflozin 10 mg once daily as monotherapy and as add-on therapy to other AHAs was generally well tolerated in patients with T2D in pooled data from 13--30 placebo-/active comparator-controlled phase 2b/3 clinical trials of 24 to ≤ 208 weeks' duration \[[@CR38]\]. In a pooled analysis of 13, placebo-controlled trials of 12--24 weeks' duration, treatment-emergent adverse events (AEs) were reported in 60% (1416/2360) of dapagliflozin and 56% (1279/2295) of placebo recipients, with 4% of patients in each group discontinuing therapy because of these events. The most common (incidence ≥ 3%) treatment-emergent AEs with dapagliflozin were nasopharyngitis (5 vs. 6% with placebo), diarrhoea (3 vs. 4%), headache (3 vs. 4%), upper respiratory tract infections (3 vs. 4%), urinary tract infection (UTIs; 4 vs. 3%) and back pain (4 vs. 2%). Serious adverse events (SAEs) occurred in 5% of patients in each group and resulted in treatment discontinuation in 0.7% of dapagliflozin and 1% of placebo recipients; deaths were infrequent in both groups (0.3 and 0.2%, respectively) \[[@CR38]\]. In the DECLARE-TIMI 58 trial, significantly more dapagliflozin than placebo recipients discontinued the trial regimen because of AEs (8 vs. 7%; *p* = 0.01), but significantly fewer dapagliflozin than placebo recipients had SAEs (34 vs. 36%; p \< 0.001) (safety population *n* = 8574 and 8569 in the respective groups) \[[@CR25]\]. The most common (incidence \> 2%) SAEs were unstable angina (2.8 vs. 2.8%) and acute MI (2.7 vs. 2.3%) \[[@CR25]\].

Adverse Events of Special Interest {#Sec12}
----------------------------------

Hypoglycaemia occurred in 14% of dapagliflozin and 12% of placebo recipients in the 13-study pooled analysis \[[@CR38]\]. Three major hypoglycaemic events were reported in the dapagliflozin group and two in the placebo group, with most events occurring in patients receiving insulin as background therapy; one event in a patient receiving dapagliflozin plus insulin and metformin resulted in discontinuation of therapy \[[@CR38]\]. In DECLARE-TIMI 58, major hypoglycaemic events occurred in significantly fewer dapagliflozin than placebo recipients (0.7 vs. 1.0%; *p* = 0.02) \[[@CR25]\].

Genital infections were more frequent with dapagliflozin than placebo in the 13-study pooled analysis (5.5% vs. 0.6%), occurring at least twice as often in women than in men in both treatment groups \[[@CR38]\]. All genital infections were of mild or moderate severity, with only 0.2% of patients in the dapagliflozin group and none in the placebo group requiring treatment discontinuation \[[@CR38]\]. UTIs were reported in 5% of dapagliflozin and 4% of placebo recipients in this analysis, occurring almost five times more frequently in women than in men, regardless of the treatment group. Most UTIs were of mild or moderate severity, had flora consistent with those in patients with T2D, were not kidney infections and did not require discontinuation of therapy (UTI-related discontinuation rate ≤ 0.2% in both groups). Most patients with genital infections or UTIs in both treatment groups responded to initial antimicrobial therapy and did not require additional treatment \[[@CR38]\]. Results from DECLARE-TIMI 58 supported the findings of the pooled analysis, with genital infections being more common with dapagliflozin than placebo (0.9 vs. 0.1%; *p* \< 0.001), while there was no significant between-group in the incidence of UTIs (1.5 vs. 1.6%) \[[@CR25]\]. Genital infections reported as SAEs were rare in both treatment groups in DECLARE-TIMI 58 (two events in each group). Fournier's gangrene (necrotising fasciitis of the perineum) was reported in one dapagliflozin and five placebo recipients \[[@CR25]\]; owing to the risk of this rare, but serious and potentially life-threatening event, patients should be advised to seek medical attention if they experience symptoms, and if Fournier's gangrene is suspected, dapagliflozin should be discontinued and prompt treatment should be instituted \[[@CR7]\].

AEs of renal function occurred in 3% of dapagliflozin and 2% of placebo recipients in the 13-study pooled analysis, occurring more frequently in patients with baseline eGFR \< 60 mL/min/1.73 m^2^ (vs. ≥ 60 mL/min/1.73 m^2^; 19 vs. 1% in the dapagliflozin group) and those aged ≥ 65 years (vs. \< 65 years; 8 vs. 2% in the dapagliflozin group) \[[@CR38]\]. The most common renal AEs were decreased renal creatinine clearance (1.1 vs. 0.7%) and renal impairment (0.8 vs. 0.5%), which were mostly transient, mild/moderate in severity and not accompanied with marked abnormalities of renal function. eGFR declined initially with dapagliflozin and returned towards baseline levels during treatement (mean change from baseline in the dapagliflozin group was − 4.5 and − 1.5 mL/min/1.73 m^2^ at weeks 1 and 24, respectively) \[[@CR38]\]. In DECLARE-TIMI 58, the incidence of acute kidney injury was significantly lower with dapagliflozin than placebo (1.5 vs. 2.0%; *p* = 0.002) \[[@CR25]\].

In the 13-study pooled analysis, volume depletion-related AEs (hypotension, hypovolaemia and dehydration) were reported in 1.1% of dapagliflozin and 0.7% of placebo recipients, with half of the events in both groups occurring during the first 8 weeks of therapy (19 and 18% of AEs in the respective groups occurred within the first 2 weeks) \[[@CR38]\]. Regardless of the treatment group, volume depletion-related AEs were more frequent in patients using loop diuretics than in those not using them (incidence 2.5-fold higher), and in patients with eGFR \< 60 mL/min/1.73 m^2^ than in those with eGFR ≥ 60 mL/min/1.73 m^2^ (incidence ≈ twofold higher). In the dapagliflozin group, patients aged ≥ 65 years were also more likely (incidence ≈ twofold higher) to have volume depletion-related AEs than patients aged \< 65 years \[[@CR38]\]. In DECLARE-TIMI 58, there was no significant difference between dapagliflozin and placebo recipients for symptoms of volume depletion (2.5 vs. 2.4%) \[[@CR25]\]. Dapagliflozin is not recommended for patients receiving loop diuretics \[[@CR7]\].

Treatment with dapagliflozin was associated with small increases in parathyroid hormone, with larger increases seen in patients with higher baseline parathyroid levels \[[@CR7], [@CR14], [@CR39]\]. No bone loss was observed with dapagliflozin during 2 years' therapy in patients with normal or mild renal impairment \[[@CR7], [@CR40]\]. Fractures were infrequent with dapagliflozin and placebo in the 13-study pooled analysis (0.3 vs. 0.7%) \[[@CR38]\]; in DECLARE-TIMI 58, there was no significant between-group difference in fracture rate (5.3 vs. 5.1%) \[[@CR25]\].

SGLT2 inhibitors, including dapagliflozin, have been associated with rare cases of diabetic ketoacidosis \[DKA; hyperglycaemia (\> 250 mg/dL), anion gap acidosis and increased plasma ketones\], including life-threatening and fatal cases \[[@CR7]\]. In a pooled analysis of 21 placebo-/active comparator-controlled trials of ≤ 208 weeks' duration (*n* = 5936 in dapagliflozin and 3403 in control groups), one SAE of DKA (which may have occurred because of insulin dose reduction), two AEs of ketonuria and one AE of metabolic acidosis were reported with dapagliflozin versus no events in the control group (estimated incidence of DKA alone 0.02%; 95% CI 0.004--0.059 and of DKA/metabolic acidosis 0.03%; 95% CI 0.01--0.09) \[[@CR38]\]. In DECLARE-TIMI 58, DKA occurred in significantly more dapagliflozin than placebo recipients (0.3 vs. 0.1%; *p* = 0.02) \[[@CR25]\]. Prior to initiating dapagliflozin, factors in patients' history that may predispose them to ketoacidosis should be taken into consideration \[[@CR7]\]. The risk of DKA should be considered if non-specific symptoms (e.g. nausea, vomiting, anorexia) occur, and treatment should be discontinued if DKA is confirmed. Patients with euglycaemic DKA (DKA without hyperglycaemia) may need glucose in addition to standard treatment for DKA, and dapagliflozin should be discontinued if DKA occurs \[[@CR7]\].

In a 21-study pooled analysis, although the incidence rate ratio (IRR) associated with dapagliflozin was above 1 for some tumours \[bladder (IRR 5.2), breast (2.5), pancreatic (1.8)\] and below 1 for other tumours \[e.g. blood and lymphatic (0.4), renal tract (0.4)\], the overall incidence rate of malignancies did not differ significantly between the dapagliflozin and control groups \[1.5 vs. 1.5%; IRR 1.03; 95% CI 0.7--1.5\] \[[@CR41]\]. In DECLARE-TIMI 58, bladder cancer occurred in fewer dapagliflozin than placebo recipients (0.3 vs. 0.5%; *p* = 0.02), and there was no between-group difference in the rate of breast cancer (0.4 vs. 0.4%) \[[@CR25]\].

Lower limb amputations were reported infrequently in the dapagliflozin and control groups (0.1 vs. 0.2%) in a 30-study pooled analysis of placebo-/active comparator-controlled trials of ≥ 12 weeks' duration (*n* = 9195 in dapagliflozin and 4629 in control groups) \[[@CR38]\]. The time to amputation was similar in both groups and patients who had an amputation had a high prevalence of risk factors (e.g. neuropathy, CVD, dyslipidaemia and nephropathy) \[[@CR38]\]. The rate of amputation did not differ significantly between dapagliflozin and placebo recipients in DECLARE-TIMI 58 (1.4 vs. 1.3%) \[[@CR25]\].

Cardiovascular Safety {#Sec13}
---------------------

A prespecified meta-analysis of CV events from 21 placebo-/active comparator-controlled phase 2b/3 clinical studies of ≤ 208 weeks' duration indicated that treatment with dapagliflozin was not associated with an increased CV risk in patients with T2D, and suggested a potential CV benefit with treatment, as evidenced by HRs of \< 1 for CV outcomes \[[@CR42]\]. In the dapagliflozin and control groups, the event rate/100 patient-years (pt-y) of MACE plus unstable angina was 1.5 versus 2.2 in the overall population (HR 0.79; 95% CI 0.58--1.1), 2.9 versus 3.8 in patients with CVD (HR 0.81; 95% CI 0.56--1.16) and 4.2 versus 5.1 in elderly (aged ≥ 65 years) patients with CVD risk (HR 0.82; 95% CI 0.5--1.37). DECLARE-TIMI 58 confirmed the CV safety of dapagliflozin in patients with T2D who had or were at risk of ASCVD, demonstrating noninferiority between dapagliflozin and placebo for the primary composite safety outcome of MACE (*p* \< 0.001 for noninferiority), and superiority for one of the two dual composite efficacy outcomes (CV death/HHF; Sect. [3.2](#Sec8){ref-type="sec"}) (Table [3](#Tab3){ref-type="table"}) \[[@CR25]\].

Dosage and Administration {#Sec14}
=========================

In the EU, dapagliflozin is approved for use as monotherapy (in patients who are intolerant of metformin) and add-on combination therapy (with other glucose-lowering agents, including insulin) in patients with T2D when diet and exercise alone do not provide adequate glycaemic control \[[@CR7]\]. The recommended dose of dapagliflozin is 10 mg once daily administered orally, with or without food. When dapagliflozin is used in combination with insulin or insulin secretagogues (e.g. sulfonylureas), a lower dose of insulin or insulin secretagogues may be required because of an increased risk of hypoglycaemia. Dapagliflozin should not be initiated in patients with GFR \< 60 mL/min and its use should be discontinued in patients with GFR persistently \< 45 mL/min. No dosage adjustment is required based on renal function or in patients with mild or moderate hepatic impairment. In patients with severe hepatic impairment, dapagliflozin should be initiated at a dose of 5 mg/day, and if well tolerated the dose should be increased to 10 mg/day \[[@CR7]\]. Local prescribing information should be consulted for further information, including dosage and administration details, contraindications, warnings and precautions.

Place of Dapagliflozin in the Management of T2D {#Sec15}
===============================================

The aim of treatment in T2D is to prevent complications and optimize patient quality of life \[[@CR43]\]. The 2018 American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) consensus guidelines \[[@CR43]\] and the 2019 ADA guidelines \[[@CR44]\] recommend a patient-centred approach for the management of glycaemia and CV risk factors in T2D. Glycaemic targets should be individualized based on the risk of adverse events (e.g. hypoglycaemia and bodyweight gain), patient characteristics (e.g. comorbidity and patient frailty) and patient preference and goals \[[@CR43]\]. Several classes of AHAs with different mechanisms of action are available for use in T2D. Metformin (unless contraindicated or not tolerated) and comprehensive lifestyle changes (including bodyweight management and physical activity) are first-line therapy. The choice of other AHAs should be individualized based on patient factors (including history of CVD, bodyweight, hypoglycaemic risk and CKD), the cost of treatment and patient preference \[[@CR43]\]. CVD is the major cause of mortality in T2D, with MI and stroke accounting for ≈ 80% of all deaths \[[@CR45]\]. Therefore, it is important that the AHA selected to improve glycaemic control in patients with T2D does not aggravate, and preferably improves, CV risk factors and reduces CV morbidity and mortality \[[@CR45]\].

SGLT2 inhibitors are a relatively new class of oral AHAs that reduce plasma glucose levels by increasing urinary glucose excretion \[[@CR46]\]. Because of their insulin-independent mechanism of action, SGLT2 inhibitors can be combined with other AHAs (including insulin) with minimal risk of hypoglycaemia \[[@CR46]\]. Currently approved SGLT2 inhibitors in the EU include dapagliflozin, canagliflozin, empagliflozin and ertugliflozin, which are administered orally once daily. Dapagliflozin is a potent, highly selective SGLT2 inhibitor (Sect. [2](#Sec2){ref-type="sec"}) with proven efficacy and safety in patients with T2D (Sect. [3](#Sec3){ref-type="sec"}). In well-designed phase 3--4 clinical trials, dapagliflozin once daily as monotherapy and combination therapy with other AHAs, provided effective glycaemic control and reduced bodyweight and BP in a broad spectrum of T2D patients, including those with hypertension and/or CVD (Sect. [3](#Sec3){ref-type="sec"}). Evidence from real-world studies supported the efficacy of dapagliflozin in patients with T2D (Sect. [3.3](#Sec10){ref-type="sec"}).

Additionally, dapagliflozin was noninferior in terms of MACE and significantly lowered the rate of CV death and HHF relative to placebo in the large DECLARE-TIMI 58 CV outcomes trial in patients at high risk for CV events, with the between-group difference largely attributed to a lower rate of HHF with dapagliflozin (Sect. [3.2](#Sec8){ref-type="sec"}). Dapagliflozin also reduced the likelihood of progression of renal disease, although statistical significance of these findings was not demonstrated because of hierarchical testing (Sect. [3.2](#Sec8){ref-type="sec"}). The CV and renal benefits with dapagliflozin were consistent across subgroups, suggesting treatment benefits across a broad patient population, regardless of history of ASCVD, HF or CKD at baseline (Sect. [3.2.1](#Sec9){ref-type="sec"}). Other subgroup analyses suggested that dapagliflozin reduced both MACE and CV death/HHF in high-risk patients with T2D and prior MI \[[@CR29]\], and reduced CV death/HHF to a greater extent in patients with HFrEF than in those without HFrEF (mainly because of a larger reduction in CV death in patients with HFrEF) \[[@CR30]\] (Sect. [3.2.1](#Sec9){ref-type="sec"}). The ongoing phase 3 DAPA-HF (NCT03036124) trial in patients with confirmed HFrEF and the phase 3 DELIVER (NCT03619213) and phase 4 PRESERVED-HF (NCT03030235) trials in patients with preserved ejection fraction HF are further evaluating the effects of dapagliflozin in these patient subgroups, while the phase 3 DAPA-CKD (NCT03036150) trial in patients with CKD is assessing whether dapagliflozin delays the progression of kidney disease.

Dapagliflozin was generally well tolerated, with a low risk of hypoglycaemia and drug class-related AEs, including AEs of volume depletion, lower limb amputations, acute kidney injury and bladder cancer (Sect. [4](#Sec11){ref-type="sec"}). DKA (rare) and genital infections (common), also drug-class related, were reported more frequently with dapagliflozin than placebo; Fournier's gangrene was reported in one dapagliflozin and five placebo recipients in DECLARE-TIMI 58 (Sect. [4.1](#Sec12){ref-type="sec"}).

In addition to DECLARE-TIMI 58, CV and renal benefits with SGLT2 inhibitors were also seen in the EMPA-REG OUTCOME trial of empagliflozin \[[@CR27]\] and the CANVAS Program for canagliflozin \[[@CR47]\]. EMPA-REG OUTCOME exclusively enrolled patients with ASCVD, while DECLARE-TIMI 58 and the CANVAS Program had only 41% and 65% of patients with established ASCVD \[[@CR25], [@CR27], [@CR47]\]. In all three CV outcomes trials, a more consistent and robust effect of SGLT2 inhibitors was seen for the prevention of HF and renal outcomes than in terms of atherosclerotic CV events \[[@CR25]\]. This difference may be because of the mechanism of action of SGLT2 inhibitors on the kidney and other effects, such as natriuresis, reduction in BP and improvement in endothelial function \[[@CR25]\]. Across the trials, SGLT2 inhibitors also appeared to moderately reduce the risk of MACE in patients with ASCVD, but not in patients with multiple risk factors \[[@CR48]\]. However, in contrast to results from EMPA-REG OUTCOME, the rate of CV death and all-cause death was not significantly reduced in DECLARE-TIMI 58, which may be because of differences between the drugs or between the study designs \[[@CR25]\].

Results from a recent meta-analysis of the three CV outcome trials of SGLT2 inhibitors were consistent with the findings from the individual trials, demonstrating robust benefits in terms of reducing HHF and progression of renal disease, and moderate benefits in terms of MACE, largely in patients with ASCVD \[[@CR48]\]. Several mechanisms have been proposed to explain the CV benefits with SGLT2 inhibitors, including improvement in ventricular loading conditions, improvement in cardiac metabolism and bioenergetics, inhibition of myocardial Na^+^/H^+^ exchange, reduction of necrosis and cardiac fibrosis, as well as alteration in adipokines, cytokine production and epicardial adipose tissue mass \[[@CR49]\]

Among other AHAs that have been assessed in CV outcome trials, the GLP-1RAs liraglutide (LEADER) and semaglutide (SUSTAIN-6) significantly reduced the likelihood of MACE in patients with T2D, while exenatide (EXSCEL) and lixisenatide (ELIXA) did not demonstrate either a CV benefit or harm \[[@CR43], [@CR50]\]. No significant effect of GLP-1RAs on HHF was observed in the CV outcome trials \[[@CR43], [@CR50]\]. Results from a recent meta-analysis suggested that SGLT2 inhibitors reduced the risk of HHF to a greater extent than GLP-1RAs (SGLT2 inhibitors vs. GLP-1RAs: HR 0.71), while there was no significant difference between SGLT2 inhibitors and GLP-1RAs for the reduction in the risk of MACE (GLP-1RAs vs. SGLT2 inhibitors: HR 1.02) \[[@CR51]\]. In CV outcome trials assessing DPP-4is, sitagliptin (TECOS), saxagliptin (SAVOR-TIMI 53) and alogliptin (EXAMINE) demonstrated CV safety, but no CV benefit, although saxagliptin was associated with a 27% greater (*p* = 0.007) risk of HHF than placebo \[[@CR43], [@CR50]\]. In terms of renal outcomes, unlike SGLT2 inhibitors that significantly reduced albuminuria and the decline in eGFR, GLP-1RAs were generally associated with significant reductions in albuminuria, but had no significant effect on eGFR, while the effect of DPP-4is on renal outcomes is unclear and needs further assessment \[[@CR52]\].

CV benefits with SGLT2 inhibitors have also been seen in large real-world studies, including the observational CVD-REAL study that enrolled \> 300,000 propensity score-matched T2D patients across six countries (USA, UK, Norway, Denmark, Sweden and Germany) \[[@CR53]\]. Treatment with an SGLT2 inhibitor was associated with a lower risk of death (HR 0.49; *p* \< 0.001) and HHF (HR 0.61; *p* \< 0.001) \[[@CR53]\], as well as a modestly lower risk of MI (HR 0.85; *p* = 0.05) and stroke (HR 0.83; *p* = 0.02) in patients newly initiated on an SGLT2 inhibitor (of the exposure time, 53, 42, and 5% of patients received canagliflozin, dapagliflozin and empagliflozin, respectively) or another AHA (*n* = 154,528 patients/group). In a subgroup analysis, SGLT2 inhibitors reduced the risk of HF regardless of pre-existing CVD, a finding consistent with the results of clinical CV outcome trials \[[@CR54]\]. Cardioprotective effects of SGLT2 inhibitors were also seen in the CVD-REAL Nordic (Denmark, Norway and Sweden; *n* = 40,908) \[[@CR55]\] and CVD-REAL 2 (Asia Pacific, the Middle East and North American regions; *n* = 235,064) \[[@CR56]\] studies, which showed that initiation of an SGLT2 inhibitor was associated with a lower risk of CV events (including MACE and HHF) and all-cause death.

Given the CV benefits of SGLT2 inhibitors and GLP-1RAs, the recent ADA/EASD consensus guidelines \[[@CR43]\] and the ADA guidelines \[[@CR44]\] recommend that history of CVD be considered very early during treatment selection for patients with T2D. In patients with established ASCVD who do not achieve HbA~1c~ target with metformin (or if metformin is not tolerated or contraindicated), the addition of an SGLT2 inhibitor or GLP-1RA with proven CVD benefit is recommended. In those with HF or CKD, the addition of an SGLT2 inhibitor with evidence of reducing HF and/or CKD progression is preferred, and if the SGLT2 inhibitor is not tolerated or contraindicated, the addition of a GLP-1RA with proven CKD benefit is recommended. If HbA~1c~ still remains above target and further intensification is required (or SGLT2 inhibitor or GLP-1RA is not tolerated), the guidelines recommend addition of the other drug class with proven CV benefit (GLP-1RA or SGLT2 inhibitor), a DPP-4i (if not on GLP-1RA; not saxagliptin in the setting of HF), basal insulin, a thiazolidinedione (avoid in the setting of HF) or sulfonylurea. SGLT2 inhibitors are also recommended as second- and subsequent-line options for patients without history of ASCVD or CKD and with a compelling need to minimize hypoglycaemia or bodyweight \[[@CR43], [@CR44]\].

To conclude, oral dapagliflozin once daily improves glycaemic control, bodyweight and BP, and reduces the risk of CV death/HHF and possibly progression of renal disease, providing an important option for the management of a broad patient population, regardless of the history of CVD.
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